Use our chat feature to speak with one of our expert consultants who can help you identify if medical cannabis can help you.
7 min read
Emily Ledger
The medicinal potential of cannabis and its derivatives has been a focus of medical research for hundreds of years. Yet, there remains a significant number of unknowns around this complex and versatile plant. With that in mind, we’re taking a closer look at some of the most significant medical cannabis research published so far in 2024.
Medical cannabis has now been legalised in a number of countries around the world, including the UK. Moreover, acceptance of the medicinal value of this ancient plant - among the public, lawmakers, and healthcare professionals - is becoming increasingly widespread. Observational studies, clinical trials, and scientific reviews are crucial in improving our understanding of the medicinal mechanisms of cannabis and further improving access to these potentially life-changing medicines.
So, let’s look at some of the most noteworthy breakthroughs in medical cannabis published so far this year.
In April, a new double-blind, placebo-controlled trial was published in the Journal, Drug and Alcohol Dependence. The study aimed to assess whether cannabis terpenoid, D-Limonene, can mitigate the acute anxiogenic effects of THC in healthy adults.
Twenty participants completed nine sessions in which they inhaled vaporised THC alone (15mg or 30mg), D-Limonene (1mg or 5 mg), the same doses of both THC and D-Limonene together, or placebo.
The study found that while administration of THC alone was associated with higher ratings of anxiousness, nervousness, and paranoia, combined administration of 30mg THC and 15 mg D-limonene significantly reduced ratings of these anxiety-like effects. The authors of the study concluded that D-Limonene is potentially able to mitigate the anxiety-inducing effects of THC - a promising finding for future trials and prescribing of medical cannabis for anxiety.
In another randomised, double-blind, placebo-controlled crossover trial, published in February, researchers aimed to examine the efficacy of medical cannabis for the treatment of acute migraine. A total of 92 participants were treated for four migraine attacks, each time using a different variant. This included vaporising a THC-dominant variant,(6% THC), a CBD-dominant (11% CBD) cultivar, a 6% THC+11% CBD variant, and a placebo.
The THC+CBD was superior to placebo at achieving pain relief, pain freedom, and ‘most bothersome symptom’ freedom at 2 hours, as well as sustained pain freedom at 24 hours and sustained MBS freedom at 24 and 28 hours. Moreover, the THC-dominant formulation was superior to placebo for pain relief at two hours post-treatment.
This adds to a relatively limited evidence base indicating the potential benefit of medical cannabis for migraine.
A second double-blind, placebo-controlled, randomised trial also assessed an oral solution of CBD in patients with mild to moderate anxiety. The multicenter trial enrolled 178 participants from across India who were randomised to receive CBD or placebo for the treatment of mild to moderate anxiety.
The oral CBD solution was found to be safe with no serious adverse events reported. Moreover, participants in the CBD group reported greater improvements in anxiety and sleep compared with the placebo group. The findings further support the potential of cannabis-based medicines in the treatment of anxiety - which represents an increasing burden on society.
In September, an observational study assessing changes in health-related quality of life following the initiation of medical cannabis treatment was published in the Journal of Cannabis Research. The study followed 438 participants prescribed medical cannabis for any of more than 20 qualifying conditions at baseline (before medical cannabis treatment) and three months.
Quality of life was measured across eight domains: physical functioning, role limitations due to physical health problems, emotional well-being, role limitations due to emotional problems, social functioning, energy/fatigue, bodily pain, and general health. Improvements were observed in all eight domains after three months of medical cannabis treatment.
The study will continue to collect outcome data from participants 6, 9, and 12 months. Nonetheless, the current findings demonstrate the potentially significant effect of medical cannabis treatment on short-term quality of life in patients with a wide range of medical conditions.
In the summer, self-reported data on cannabis use and perceived efficacy were collected from chronic musculoskeletal (MSK) pain patients at the Orthopaedic Clinic at the University Health Network, Toronto, Canada. The authors of the study aimed to examine the rate, patterns of use, and perceived efficacy of cannabis among MSK pain patients.
Of the 629 participants, almost a quarter (23%) reported past or present cannabis use to manage their MSK pain. Of those, 63.7% perceived cannabis to be very or somewhat effective and 26.6% considered it to be slightly effective at managing their pain. Furthermore, among non-users, almost two-thirds expressed an interest in cannabis to manage their pain; however, they reported barriers to access, including lack of knowledge and stigma.
In March, a real-world observational study was published in the BJPsych Open journal. The study aimed to “document the prevalence of depression among individuals seeking [medical cannabis] to treat PTSD and to examine whether the effectiveness of [medical cannabis] varies by depression status.
The researchers assessed data from 238 people with PTSD seeking medical cannabis treatment, in addition to follow-up data from 116 people. Self-reported PTSD symptoms were assessed at baseline and three months; a total of 77% of participants met screening criteria for depression, which is associated with higher levels of PTSD symptomatology, and poorer quality of life, sleep, and general health.
The study found that PTSD symptoms improved significantly following three months of medical cannabis treatment, with a greater improvement observed in patients with comorbid depression. These findings once again highlight the potential of medical cannabis for common mental health conditions.
In 2021, the French government launched their medical cannabis pilot programme - a trial to provide up to 3,000 patients with access to cannabis-based medicines for five approved indications (refractory neuropathic pain, drug-resistant epilepsy, spasticity in multiple sclerosis (MS), cancer-related symptoms, and palliative care). After being extended earlier this year, the pilot programme will now run until the end of 2024; however, some key findings have been announced.
According to a recent news report, the trial has had “overwhelmingly positive” early results with around 60% of patients finding medical cannabis beneficial for relieving their symptoms. As a result of these and other findings, the - national agency for the safety of medicines and health products - has announced that medical cannabis will be made available in France in 2025.
2024 has been a great year for medical cannabis research, with new studies reinforcing existing evidence of the diverse potential of these medications. However, they often also highlight the persistent barriers to access and, in some cases, further meaningful research.
It is our hope that future research will not only continue to improve our understanding of medical cannabis but also serve to remove stigma and improve access to patients who are still in need of effective treatment options.
It is important to seek medical advice before starting any new treatments. The patient advisors at Releaf are available to provide expert advice and support. Alternatively, click here to book a consultation with one of our specialist doctors.
Get comprehensive care, convenience, and confidence with an all-in-one treatment plan.
Am I eligible?Emily, an accomplished content writer with a specialisation in cannabis and alternative health, leverages her five years in the sector to enhance education and diminish stigma around medicinal cannabis use.
All of our articles are written by medical cannabis experts, guided by strict sourcing guidelines, and reference peer-reviewed studies and credible academic research. Our expert clinical team and compliance specialists provide valuable insights to ensure accuracy when required. Learn more in our editorial policy.
Need more help?
November is National COPD Awareness Month, a time dedicated to raising awareness of Chronic Obstructive Pulmonary Disease (COPD) and the prevention and treatment of chronic lung disease. In honour of this important event, we’re taking a closer look at the relationship between medical cannabis and chronic lung disease and answering the question: “Can I vape medical cannabis if I have COPD?”
Emily Ledger
Medical cannabis treatment is quite an individual process, which means there is no one-size-fits-all answer to the question of how often you should see your doctor. Each and every patient we see here at Releaf responds at least slightly differently to their treatment protocol. This is the main reason our world-class clinical team takes such a personalised approach to each patient's care and why it is essential that all patients see their doctor regularly.
Sam North
Disability History Month, taking place from 14 November— 20 December highlights the history of the equality and human rights struggles of disabled individuals in the UK.
Sarah Sinclair
